immuno-therapy

You are here

We recommend to visit

Summary

Introduction. A proportion of patients with acute B-lymphoblastic leukemia fails to achieve a remission or does not tolerate a standardized chemotherapy. Immunotherapy with anti-CD agents might be an indispensable supplement to the treatment of these patients. The aim of the study was to investigate the expression patterns of potential immunological targets (CD20, CD22 and CD33) in patients with B-ALL.

Undefined
© 2022, Lithuanian Society of Laboratory Medicine